Ecnoglutide, a novel biased GLP-1 receptor agonist that favors cAMP pathway activation over ฮฒ-arrestin recruitment, may provide enhanced glycemic control in type 2 diabetes , but its efficacy compared to other GLP-1 agonists is not fully established. To address this gap, a study has evaluated the non-inferiority and superiority of ecnoglutide versus dulaglutide in 623 patients with type 2 diabetes. The study found that ecnoglutide 0.6 mg and 1.2 mg significantly reduced HbA1c by 1.91% and 1.89%, respectively, compared with dulaglutide 1.5 mg, which reduced HbA1c by 1.65% at week 32.
Estimated treatment differences versus dulaglutide were โ0.26% for ecnoglutide 0.6 mg and โ0.24% for ecnoglutide 1.2 mg. HbA1c reductions were sustained through week 52. Treatment discontinuation due to adverse events occurred in 3% of patients in the ecnoglutide 0.6 mg group, 4% in the 1.2 mg group, and 3%โฆ
